KEI December 2, 2016 meeting on the delinkage of R&D costs from drug prices

KEI is holding a December 2, 2016 meeting on the delinkage of R&D costs from drug prices.

The venue will be US Senate Hearing Room SD-106, Dirksen Office Building. The meeting will take place from 9:00am to 2:00pm.

A copy of the agenda is available here.

For more information about delinkage, see: http://delinkage.org.

To register for the event, please fill out this form: https://goo.gl/forms/AbP2npqLRLYneLjk1.

For more information about the event, contact claire.cassedy@keionline.org.

The topics discussed at the meeting will include:

What is delinkage, and why is it important?

Reform of pull mechanisms

What are end product prizes, and how do they work?
What is the open source dividend, how does it work, and why is it important?
How interim results prizes work

Making global norms for R&D funding (both push and pull)

Strategies for progressive delinkage

Next steps

Attached is the most recent agenda (as updates are released, we will update the agenda below). Speakers and respondents include:

• Aidan Hollis, Professor, Department of Economics, University of Calgary
• Dean Baker, co-Director of the Center for Economic and Policy Research
• Diane Singhroy, Scientific Advisor, Knowledge Ecology International
• Ellen ‘t Hoen, LLM. Medicines Law & Policy and Global Health Unit, University Medical Center Groningen, University of Groningen, The Netherlands.
• James Love, Knowledge Ecology International (KEI)
• James L. McGee, CEBS, Executive Director, Transit Employees’ Health & Welfare Fund
• Joe Larsen, Ph.D., Deputy Director (acting), Biomedical Advanced Research Development Authority (BARDA)
• John Wilbanks, Chief Commons Officer at Sage Bionetworks and a Senior Fellow at the Ewing Marion Kauffman Foundation and at FasterCures
• Judit Rius, Médecins sans frontières
• Katy Athersuch, Medical Innovation & Access Policy Adviser
• Manon Ress, Union for Affordable Cancer Treatment (UACT)
• Patrick Kilbride, Executive Director, International Intellectual Property, GIPC at U.S. Chamber of Commerce
• Rachel Cohen, DNDi
• Rishab Ghosh, Maastricht University
• Rob Weissman, President, Public Citizen
• Sakiko Fukuda-Parr. Professor of International Affairs, The New School in New York, member of the UN Secretary General High Level Panel on Access to Medicine.
• Tim Hubbard, Professor of Bioinformatics, King’s College London